Analysis of serum cancer procoagulant activity and its possible use as a tumor marker.
The two objectives of the study were to determine whether a procedure could be developed for measuring cancer procoagulant (CP) activity in human serum and if this procedure provided a method for distinguishing people with cancer from those without cancer. A procedure was developed for processing human serum such that the activity of other coagulation enzymes would be minimized and the activity of cancer procoagulant could be measured. In a blinded study, we collected serum from 61 individuals in serum separator tubes, removed the clot by centrifugation, extracted the serum with a simple, single step procedure and analyzed the extract for CP activity. The results indicate that this test could correctly identify about 92% of the cancer patient serum samples and about 75% of the non-cancer patients serum samples, for an overall accuracy of about 85%.
Gordon
S G
SG
Univ. of Colorado Health Sciences Center, Denver, 80262.
Benson
B
B
D014408:Biomarkers, Tumor / Q000097:blood*; D001779:Blood Coagulation Factors / Q000032:analysis*; D001780:Blood Coagulation Tests; D003546:Cysteine Endopeptidases / Q000097:blood*; D005168:Factor VII Deficiency / Q000097:blood; D005260:Female; D006801:Humans; D008297:Male; D009363:Neoplasm Proteins / Q000097:blood*; D009369:Neoplasms / Q000097:blood* / Q000175:diagnosis / Q000201:enzymology; D011237:Predictive Value of Tests
D014408:Biomarkers, Tumor; D001779:Blood Coagulation Factors; D009363:Neoplasm Proteins; D003546:Cysteine Endopeptidases; C030910:cancer procoagulant